BD - Earth day 2024

Mayo Clinic and SimBioSys Forge a Strategic Partnership to Propel AI-driven Digital Precision Medicine Platform for Cancer Patients

Tuesday, January 02, 2024

SimBioSys and Mayo Clinic have recently entered into a collaborative partnership to transform precision medicine for breast cancer using advanced AI and biophysical modeling. This joint venture aims to develop cutting-edge cloud-based clinical tools that guide comprehensive decision-making for early-stage breast cancer patients. The tools will cover personalized surgical planning, treatment strategies, drug selection, and risk assessment. With the ever-evolving landscape of breast cancer care, the collaboration seeks to customize treatments to improve the quality of life for patients without compromising outcomes.

SimBioSys, a TechBio company, has assembled a team of experts to develop TumorSightTM, a cloud-based platform currently awaiting FDA review. The platform's first product utilizes patient-specific DCE-MRI imaging to create a 3D digital model of tumors. This groundbreaking tool empowers surgical oncologists with spatial visualizations for more effective surgical planning. The clear 3D "digital twin" renderings provide instant insights into the tumor within the context of auto-segmented anatomical structures such as skin, vessels, chest, fat, gland, and heart.

Mayo Clinic, recognized as a Comprehensive Cancer Center by the National Cancer Institute, has a vested interest in this technology. Any revenue generated will be channeled to support Mayo Clinic's not-for-profit mission in patient care, education, and research.





Healthcare CEO & Executive Strategy SummitHealthcare CNO SummitHealthcare CMO SummitHealthcare CFO, Financial Strategy & Revenue Cycle SummitThe Healthcare Patient Experience & Engagement Summit 2024Healthcare Innovation & Transformation Summit